Investor Presentaiton
Forward-Looking Statements
This presentation and our discussions during this conference call will include forward-looking statements and forward-looking information that
are subject to substantial risks and uncertainties, many of which are beyond our control, that could cause actual results to differ materially from
those expressed or implied by such statements and information. We include forward-looking statements about, among other topics, Pfizer's
Inflammation & Immunology pipeline, inline products and product candidates, including anticipated regulatory submissions, data read-outs, study
starts, approvals, clinical trial results and other developing data that become available, revenue contribution, growth, performance, timing of
exclusivity and potential benefits; anticipated operating and financial performance; capital allocation objectives; the proposed acquisition of
Arena Pharmaceuticals, Inc. by Pfizer; the benefits of the proposed transaction; future opportunities and strategies; growth potential; and
expectations for Arena's product pipeline and product candidates, including expected best-in-class and growth potential. Among other things,
statements regarding growth; the development or commercial potential of the product pipeline, inline products, product candidates and additional
indications, including expected clinical trial protocols, the timing of the initiation and progress of clinical trials and data read-outs from trials; the
timing for the submission of applications for and receipt of regulatory approvals; and expected breakthrough, best or first-in-class or blockbuster
status of products are forward-looking and are estimates that are subject to change and clinical trial and regulatory success. These statements
and information are subject to risks, uncertainties and other factors that may cause actual results to differ materially from past results, future
plans and projected future results. Additional information regarding these and other factors affecting such statements can be found in Pfizer's
Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and its subsequent reports on Form 10-Q, including in the sections
thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in our subsequent
reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and
www.pfizer.com, and in our press release dated December 13, 2021 regarding the proposed acquisition of Arena. Potential risks and
uncertainties also include the impact of and delays caused by COVID-19, including on sales and operations, and on employees, manufacturing,
supply chain, marketing, research and development and clinical trials. The forward-looking statements in this presentation and made during our
discussions speak only as of the original date of this presentation and we undertake no obligation to update or revise any of these statements.
Cross-trial comparisons are not based on head-to-head studies and no direct comparisons can be made.
2PfizerView entire presentation